Table 4:

Confirmation of anti-filovirus properties of novel toremifene derivatives against infectious EBOV Zaire (Kikwit variant) and MARV (Angola variant).

Compound	IC50(μM) EBOV	IC50(μM) MARV	SI EBOV	SI MARV
1	0.84 ± 0.03	3.90 ± 0.82	35	7.5
9	0.14 ± 0.01	1.56 ± 0.49	247	22
27	1.64 ± 0.13	1.78 ± 2.01	15	14
28	5.81 ± 0.83	>25	8	<2
29	2.34 ± 0.21	2.90 ± 0.15	30	25
30	0.09 ± 0.03	0.64 ± 0.12	124	18
31	0.16 ± 0.01	1.06 ± 0.15	43	7
32	0.13 ± 0.03	0.96 ± 0.22	31	4
33	0.22 ± 0.004	1.07 ± 0.06	25	5
34	0.21 ± 0.11	0.36 ± 0.08	31	18
35	0.18 ± 0.0006	0.87 ± 0.002	22	6
36	1.49 ± 0.13	2.80 ± 0.11	15	8
37	5.00 ± 0.86	3.24 ± 0.63	9	14